Which treatment is NOT typically used for HSDD?

In the context of treating Hypoactive Sexual Desire Disorder (HSDD), it is important to focus on the targeted therapies that have been specifically developed and approved for this condition. Flibanserin and Bremelanotide are both treatments designed to address HSDD in premenopausal women, with Flibanserin acting as a daily medication to increase sexual desire and Bremelanotide being used on an as-needed basis to enhance sexual desire.

Testosterone therapy, while primarily associated with enhancing libido, is also used in specific cases of HSDD, particularly in women who may have low testosterone levels contributing to their sexual dysfunction. The use of testosterone in women is subject to careful consideration and monitoring, given the complexity of hormonal treatments.

In contrast, Oxycodone, which is an opioid pain medication, is not used to treat HSDD and does not have any indication for this purpose. Opioids can actually contribute to decreased libido and sexual dysfunction as a side effect, making them counterproductive for someone suffering from HSDD. Therefore, it is clear that Oxycodone does not belong in the category of treatments typically used for Hypoactive Sexual Desire Disorder.